Myeloproliferative neoplasms (MPNs) are a closely related group of progressive blood cancers in which the bone marrow typically overproduces one of the mature blood elements. Other shared features include tendencies toward blood clotting/bleeding, organ enlargement, bone marrow scarring (fibrosis) and a possibility of transformation. Although MPNs can strike anyone at any age, most patients are afflicted in the sixth decade of life or later.
Many MPNs are characterized by the abnormal growth of white blood cells, red blood cells, and platelets – events that can be caused by genetic mutations.
Stem cell transplants may offer a cure for some myelofibrosis sufferers. But there are no known cures for most MPNs. However, patients can experience few or no symptoms for extended periods of time and many people who suffer from MPNs can enjoy longevity with proper monitoring and treatment. The identification of the JAK2 gene marker in 2005 and the CALR gene marker in 2013 have led to significant advances in the diagnosis, understanding of disease processes and treatment of MPNs.
At MPN Research Foundation, we’re committed to funding researchers in their quest to treat and ultimately cure MPNs. But even more importantly, we’re committed to providing patients, their families and the entire MPN community with advocacy, education, and resources. Working together, we can change the prognosis and create a brighter future for people whose lives are affected by this group of diseases.